Association of baseline characteristics and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (CPIs): Real-world evidence.
Danielle Crawley(Guy's and St Thomas' NHS Foundation Trust), Sharmistha Ghosh(Guy's and St Thomas' NHS Foundation Trust), Saranya Ravindra(Guy's and St Thomas' NHS Foundation Trust), Eleni Karapanagiotou(King's College London), James Spicer(King's College London), Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Kerri Beckmann(The University of Adelaide)
Cited by 1
Related Papers
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
|Cell|2020|614
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614